Citations (179)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
David J. Zahavi, Rossin Erbe, Yong-Wei Zhang, Theresa Guo, Zoe X. Malchiodi, Rachael Maynard, Alexander Lekan, Rosa Gallagher, Julia Wulfkuhle, Emanuel Petricoin, Sandra A. Jablonski, Elana J. Fertig & Louis M. Weiner. (2023) Antibody dependent cell-mediated cytotoxicity selection pressure induces diverse mechanisms of resistance. Cancer Biology & Therapy 24:1.
Read now
Read now
Yoon Sun Park, Joseph kim, Yea Seong Ryu, Jai-Hee moon, Yu Jin shin, Jeong Hee kim, Seung-Woo hong, Soo-A jung, Seul lee, Seung-Mi kim, Dae Hee lee, Do Yeon kim, Hyeseon yun, Ji-Eun you, Dong Il yoon, Chul Hee kim, Dong-In koh & Dong-Hoon jin. (2023) Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer. Cancer Biology & Therapy 24:1.
Read now
Read now
Simon Vyse & Paul H Huang. (2022) Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. Expert Review of Anticancer Therapy 22:1, pages 3-16.
Read now
Read now
Ana Marija Sola, Daniel E. Johnson & Jennifer R. Grandis. (2019) Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. Expert Opinion on Investigational Drugs 28:4, pages 351-363.
Read now
Read now
Francia Holguin, Jordi Rubió-Casadevall, Maria Saigi, Jordi Marruecos, Miren Taberna, Marc Tobed, Manuel Maños & Ricard Mesía. (2017) Cetuximab as treatment for head and neck cancer patients with a previous liver transplant: report of two cases. Journal of Chemotherapy 29:5, pages 310-313.
Read now
Read now
Rajeev Nema, Supriya Vishwakarma, Rahul Agarwal, Rajendra Kumar Panday & Ashok Kumar. (2016) Emerging role of sphingosine-1-phosphate signaling in head and neck squamous cell carcinoma. OncoTargets and Therapy 9, pages 3269-3280.
Read now
Read now
José Yélamos, Miguel Galindo, Judith Navarro, Joan Albanell, Ana Rovira, Federico Rojo & Javier Oliver. (2016) Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors. OncoImmunology 5:1.
Read now
Read now
Paola Gazzaniga, Cristina Raimondi, Chiara Nicolazzo, Raffaella Carletti, Cira di Gioia, Angela Gradilone & Enrico Cortesi. (2015) The rationale for liquid biopsy in colorectal cancer: a focus on circulating tumor cells. Expert Review of Molecular Diagnostics 15:7, pages 925-932.
Read now
Read now
Efthymia Soura, Vasiliki Chasapi & Alexander J Stratigos. (2015) Pharmacologic treatment options for advanced epithelial skin cancer. Expert Opinion on Pharmacotherapy 16:10, pages 1479-1493.
Read now
Read now
Barry Jutten & Kasper rouschop. (2014) EGFR signaling and autophagy dependence for growth, survival, and therapy resistance. Cell Cycle 13:1, pages 42-51.
Read now
Read now
Ying-dong Cheng, Hua Yang, Guo-qing Chen & Zhi-cao Zhang. (2013) Molecularly targeted drugs for metastatic colorectal cancer. Drug Design, Development and Therapy 7, pages 1315-1322.
Read now
Read now
Mari Iida, Toni M. Brand, David A. Campbell, Megan M. Starr, Neha Luthar, Anne M. Traynor & Deric L. Wheeler. (2013) Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biology & Therapy 14:6, pages 481-491.
Read now
Read now
Phuc Van Pham, Ngoc Bich Vu, Thuy Thanh Duong, Tam Thanh Nguyen, Nhung Hai Truong, Nhan Lu Chinh Phan, Tue Gia Vuong, Viet Quoc Pham, Hoang Minh Nguyen, Kha The Nguyen, Nhung Thi Nguyen, Khue Gia Nguyen, Lam Tan Khat, Dong Van Le, Kiet Dinh Truong & Ngoc Kim Phan. (2012) Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatment. OncoTargets and Therapy 5, pages 77-84.
Read now
Read now
Ana Markovic & Christine H Chung. (2012) Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma. Expert Review of Anticancer Therapy 12:9, pages 1149-1159.
Read now
Read now
Articles from other publishers (165)
Richa Vartak, Bhavesh Deore, Carlos A. Sanhueza & Ketan Patel. (2023) Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations. International Journal of Biological Macromolecules 252, pages 126413.
Crossref
Crossref
Bianca A. M. H. van Veggel, Anthonie J. van der Wekken, Marthe S. Paats, Lizza E. L. Hendriks, Sayed M. S. Hashemi, Antonios Daletzakis, Daan van den Broek, Linda J. W. Bosch, Kim Monkhorst, Egbert F. Smit & Adrianus J. de Langen. (2023)
A phase 2 trial combining afatinib with cetuximab in patients with
EGFR
exon 20 insertion–positive non–small cell lung cancer
. Cancer.
Crossref
Crossref
Vaibhavi Kardile, Atharva Kulkarni, Brinda Nadar & Tina Saldanha. (2023) Monoclonal Antibodies in Oncology: A Decade of Novel Options. Cell Biochemistry and Biophysics 81:3, pages 395-408.
Crossref
Crossref
Diana D. Novak, Olga S. Troitskaya, Anna A. Nushtaeva, Maria V. Zhilnikova, Vladimir A. Richter, Mariya I. Meschaninova & Olga A. Koval. (2023) EGFR Suppression Inhibits the Sphere Formation of MCF7 Cells Overexpressing EGFR. Acta Naturae 15:2, pages 59-69.
Crossref
Crossref
Iphigenia Gintoni, Stavros Vassiliou, George P. Chrousos & Christos Yapijakis. (2023) Review of Disease-Specific microRNAs by Strategically Bridging Genetics and Epigenetics in Oral Squamous Cell Carcinoma. Genes 14:8, pages 1578.
Crossref
Crossref
Koki Umemori, Kisho Ono, Takanori Eguchi, Hotaka Kawai, Tomoya Nakamura, Tatsuo Ogawa, Kunihiro Yoshida, Hideka Kanemoto, Kohei Sato, Kyoichi Obata, Shoji Ryumon, Hirokazu Yutori, Naoki Katase, Tatsuo Okui, Hitoshi Nagatsuka & Soichiro Ibaragi. (2023) EpEX, the soluble extracellular domain of EpCAM, resists cetuximab treatment of EGFR-high head and neck squamous cell carcinoma. Oral Oncology 142, pages 106433.
Crossref
Crossref
Aude Jehl, Ombline Conrad, Mickaël Burgy, Sophie Foppolo, Romain Vauchelles, Carole Ronzani, Nelly Etienne-Selloum, Marie-Pierre Chenard, Aurélien Danic, Thomas Dourlhes, Claire Thibault, Philippe Schultz, Monique Dontenwill & Sophie Martin. (2023) Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction. Cells 12:5, pages 733.
Crossref
Crossref
Guangyao Li, Changhai Lei & Shi Hu. 2023. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies
41
46
.
Tian Li, Changhai Lei & Shi Hu. 2023. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies
47
54
.
Mei Lan Tan, Jia Wen Yeap & Azlinah Matawali. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
32
.
Yu-Wei Lin, Hung-Cheng Su, Emmanuel Naveen Raj, Kuang-Kai Liu, Chien-Jen Chang, Tzu-Chia Hsu, Po-Yun Cheng, Rou-Hsin Wang, Yen-Her Lai, Chien-Hung Chen, Yen-Cheng Lin & Jui-I Chao. (2022) Targeting EGFR and Monitoring Tumorigenesis of Human Lung Cancer Cells In Vitro and In Vivo Using Nanodiamond-Conjugated Specific EGFR Antibody. Pharmaceutics 15:1, pages 111.
Crossref
Crossref
Mariangela De Robertis, Maria Raffaella Greco, Rosa Angela Cardone, Tommaso Mazza, Flaviana Marzano, Nikolay Mehterov, Maria Kazakova, Nikolay Belev, Apollonia Tullo, Graziano Pesole, Victoria Sarafian & Emanuela Signori. (2022) Upregulation of YKL-40 Promotes Metastatic Phenotype and Correlates with Poor Prognosis and Therapy Response in Patients with Colorectal Cancer. Cells 11:22, pages 3568.
Crossref
Crossref
Danielle Brazel, Gianna Kroening & Misako Nagasaka. (2022) Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options. BioDrugs 36:6, pages 717-729.
Crossref
Crossref
Yao Yao Yan, Xing Xing Zhang, Yun Xiao, Xiao Bao Shen, Yu Jie Jian, Yu Meng Wang, Zi Hao She, Ming Ming Liu & Xin Hua Liu. (2022) Design and Synthesis of a 2-Amino-pyridine Derivative as a Potent CDK8 Inhibitor for Anti-colorectal Cancer Therapy. Journal of Medicinal Chemistry 65:19, pages 13216-13239.
Crossref
Crossref
Saloni Ramani, Sayalee Samant & Sonal M Manohar. (2022) The story of EGFR: from signaling pathways to a potent anticancer target. Future Medicinal Chemistry 14:17, pages 1267-1288.
Crossref
Crossref
Sergio González-Rubio, Cástor Salgado, Vanesa Manzaneda-González, Mónica Muñoz-Úbeda, Rubén Ahijado-Guzmán, Paolo Natale, Víctor G. Almendro-Vedia, Elena Junquera, José Osío Barcina, Irene Ferrer, Andrés Guerrero-Martínez, Luis Paz-Ares & Iván López-Montero. (2022) Tunable gold nanorod/NAO conjugates for selective drug delivery in mitochondria-targeted cancer therapy. Nanoscale 14:22, pages 8028-8040.
Crossref
Crossref
Jordan Berlin, Anthony W. Tolcher, Cliff Ding, Jennifer G. Whisenant, Ivan D. Horak, Debra L. Wood, Paul I. Nadler, Ulla Holm Hansen, Johan Lantto, Niels Jørgen Ø. Skartved, Mikkel W. Pedersen & Amita Patnaik. (2022) First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies. Investigational New Drugs 40:3, pages 586-595.
Crossref
Crossref
Sneh Lata Gupta, Naeem Khan, Srijani Basu & Vijay Soni. (2022) B-Cell-Based Immunotherapy: A Promising New Alternative. Vaccines 10:6, pages 879.
Crossref
Crossref
W. Pao & Y.A. Nagel. (2022) Paradigms for the development of transformative medicines—lessons from the EGFR story. Annals of Oncology 33:5, pages 556-560.
Crossref
Crossref
Seyedeh Roghayeh Hamidi, Yaghoub Safdari & Mehdi Sheikh Arabi. (2022) FITC-conjugated single chain Nimotuzumab can specifically recognize and enter EGFR-overexpressing cells. International Journal of Peptide Research and Therapeutics 28:3.
Crossref
Crossref
Jonathan Poh, Kao Chin Ngeow, Michelle Pek, Kian-Hin Tan, Jing Shan Lim, Hao Chen, Choon Kiat Ong, Jing Quan Lim, Soon Thye Lim, Chwee Ming Lim, Boon Cher Goh & Yukti Choudhury. (2022) Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA. PLOS ONE 17:4, pages e0267389.
Crossref
Crossref
Xiaoqing Lu, Liwei An, Guangjian Fan, Lijuan Zang, Weiyi Huang, Junjian Li, Jun Liu, Weiyu Ge, Yuwei Huang, Jingxuan Xu, Shaoqian Du, Yuan Cao, Tianhao Zhou, Huijing Yin, Li Yu, Shi Jiao & Hongxia Wang. (2022) EGFR signaling promotes nuclear translocation of plasma membrane protein TSPAN8 to enhance tumor progression via STAT3-mediated transcription. Cell Research 32:4, pages 359-374.
Crossref
Crossref
Hu Han, Yan Li, Wan Qin, Lu Wang, Han Yin, Beibei Su & Xianglin Yuan. (2022) miR-199b-3p contributes to acquired resistance to cetuximab in colorectal cancer by targeting CRIM1 via Wnt/β-catenin signaling. Cancer Cell International 22:1.
Crossref
Crossref
Alex Friedlaender, Vivek Subbiah, Alessandro Russo, Giuseppe Luigi Banna, Umberto Malapelle, Christian Rolfo & Alfredo Addeo. (2021) EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nature Reviews Clinical Oncology 19:1, pages 51-69.
Crossref
Crossref
Moran Grossman & Elaine Adler. 2021. Protein Kinases - Promising Targets for Anticancer Drug Research. Protein Kinases - Promising Targets for Anticancer Drug Research.
Cedric S. Tremblay, Stephen B. Ting, Adam McCluskey, Phillip J. Robinson & David J. Curtis. (2021) Shutting the gate: targeting endocytosis in acute leukemia. Experimental Hematology 104, pages 17-31.
Crossref
Crossref
Yongjian Huang, Jana Ognjenovic, Deepti Karandur, Kate Miller, Alan Merk, Sriram Subramaniam & John Kuriyan. (2021) A molecular mechanism for the generation of ligand-dependent differential outputs by the epidermal growth factor receptor. eLife 10.
Crossref
Crossref
Ayushi Sharma, Samarth Kansara, Mehul Mahajan, Bhupender Yadav, Manoj Garg & Amit Kumar Pandey. (2021) Long non-coding RNAs orchestrate various molecular and cellular processes by modulating epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1867:11, pages 166240.
Crossref
Crossref
Keyun Ren, Hao Gong, Zheng Ma, Lvming Tian, Wei Ye, Xingkai Lv & Chutse Wu. (2021)
Structure and activity of an
anti‐
epidermal growth factor receptor antibody without galactose‐α‐1,3‐galactose residues
. Drug Development Research.
Crossref
Crossref
Guang Yang, Ling Huang, Hongtao Jia, Batuer Aikemu, Sen Zhang, Yanfei Shao, Hiju Hong, Galiya Yesseyeva, Chenxing Wang, Shuchun Li, Jing Sun, Minhua Zheng & Junjun Ma. (2021) NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer. Oncogene 40:41, pages 5993-6006.
Crossref
Crossref
Anna J. Boland, Anthony A. O’Kane, Richard Buick, Daniel B. Longley & Christopher J. Scott. (2021) Antibody therapy in pancreatic cancer: mAb-ye we’re onto something?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1876:1, pages 188557.
Crossref
Crossref
Jean-Baptiste Guy, Sophie Espenel, Safa Louati, Arnaud Gauthier, Max-Adrien Garcia, Nicolas Vial, Céline Malésys, Dominique Ardail, Gersende Alphonse, Anne-Sophie Wozny, Claire Rodriguez-Lafrasse & Nicolas Magné. (2021) Combining radiation to EGFR and Bcl-2 blockade: a new approach to target cancer stem cells in head and neck squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology 147:7, pages 1905-1916.
Crossref
Crossref
Mickaël Burgy, Aude Jehl, Ombline Conrad, Sophie Foppolo, Véronique Bruban, Nelly Etienne-Selloum, Alain C. Jung, Murielle Masson, Christine Macabre, Sonia Ledrappier, Hélène Burckel, Carole Mura, Georges Noël, Christian Borel, François Fasquelle, Mihaela-Alina Onea, Marie-Pierre Chenard, Alicia Thiéry, Monique Dontenwill & Sophie Martin. (2021) Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma. Cancers 13:12, pages 3038.
Crossref
Crossref
Ana Luiza Ribeiro de Souza, Amanda Cláudia Ferreira Amorim, Emílio Ramos Cintra, Natália Noronha Ferreira, Luís Antônio Dantas Silva, Tacio Gonçalves Hayasaki, Danielle Guimarães Almeida Diniz & Eliana Martins Lima. (2021) Development and validation of a rapid RP-HPLC method for simultaneous quantification of paclitaxel and cetuximab in immunoliposomes. Talanta 225, pages 121988.
Crossref
Crossref
Martha Wium, Aderonke F. Ajayi-Smith, Juliano D. Paccez & Luiz F. Zerbini. (2021) The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications. Cancers 13:7, pages 1521.
Crossref
Crossref
W. W. B. de Kort, S. Spelier, L. A. Devriese, R. J. J. van Es & S. M. Willems. (2021) Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review. Molecular Diagnosis & Therapy 25:2, pages 123-136.
Crossref
Crossref
Dahye Kim, Sanghee Lee & Kun Na. (2021)
Immune Stimulating Antibody‐Photosensitizer Conjugates via Fc‐Mediated Dendritic Cell Phagocytosis and Phototriggered Immunogenic Cell Death for
KRAS
‐Mutated Pancreatic Cancer Treatment
. Small 17:10.
Crossref
Crossref
Chongkai Wang, Ching Ouyang, May Cho, Jingran Ji, Jaideep Sandhu, Ajay Goel, Michael Kahn & Marwan Fakih. (2021)
Wild-type
APC
Is Associated with Poor Survival in Metastatic Microsatellite Stable Colorectal Cancer
. The Oncologist 26:3, pages 208-214.
Crossref
Crossref
Zeyu Lu, Nicholas L. Truex, Mariane B. Melo, Yiran Cheng, Na Li, Darrell J. Irvine & Bradley L. Pentelute. (2021) IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells. ACS Central Science 7:2, pages 365-378.
Crossref
Crossref
Nichole E. M. Kaufman, Simran Dhingra, Seetharama D. Jois & Maria da Graça H. Vicente. (2021) Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR). Molecules 26:4, pages 1076.
Crossref
Crossref
Amanda C. Sharko, Chang-Uk Lim, Martina S. J. McDermott, Chuck Hennes, Kingsavanh P. Philavong, Tiffanie Aiken, Victor V. Tatarskiy, Igor B. Roninson & Eugenia V. Broude. (2021) The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs. Cells 10:1, pages 144.
Crossref
Crossref
Toheeb A Balogun, Nureni Ipinloju, Olayemi T Abdullateef, Segun I Moses, Damilola A Omoboyowa, Akinwumi C James, Oluwatosin A Saibu, Wumi F Akinyemi & Ebenezer A Oni. (2021)
Computational Evaluation of Bioactive Compounds from
Colocasia affinis
Schott as a Novel EGFR Inhibitor for Cancer Treatment
. Cancer Informatics 20, pages 117693512110492.
Crossref
Crossref
Kelechi Nwachuku, Daniel E. Johnson & Jennifer R. Grandis. 2021. Early Detection and Treatment of Head & Neck Cancers. Early Detection and Treatment of Head & Neck Cancers
107
122
.
Dylan F. Roden, Jennifer M. Johnson, Petr Szturz, Paolo Bossi & Athanassios Argiris. 2021. Critical Issues in Head and Neck Oncology. Critical Issues in Head and Neck Oncology
277
296
.
Tejaswini P. Reddy, Dong S. Choi, Ann C. Anselme, Wei Qian, Wen Chen, Johan Lantto, Ivan D. Horak, Michael Kragh, Jenny C. Chang & Roberto R. Rosato. (2020) Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs. Breast Cancer Research 22:1.
Crossref
Crossref
Brooke N. McKnight, Seongho Kim, Julie L. Boerner & Nerissa T. Viola. (2020) Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer. Breast Cancer Research 22:1.
Crossref
Crossref
Nadia Ben Jemii, Haifa Tounsi-Kettiti, Hamza Yaiche, Najla Mezghanni, Amira Jaballah Gabteni, Emna Fehri, Chayma Ben Fayala, Sonia Abdelhak & Samir Boubaker. (2020) Dysregulated PDGFR alpha expression and novel somatic mutations in colorectal cancer: association to RAS wild type status and tumor size. Journal of Translational Medicine 18:1.
Crossref
Crossref
Nan Yao, Chen-Ran Wang, Ming-Qun Liu, Ying-Jie Li, Wei-Min Chen, Zheng-Qiu Li, Qi Qi, Jin-Jian Lu, Chun-Lin Fan, Min-Feng Chen, Ming Qi, Xiao-Bo Li, Jian Hong, Dong-Mei Zhang & Wen-Cai Ye. (2020) Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth. Signal Transduction and Targeted Therapy 5:1.
Crossref
Crossref
Maoxiao Yan, Jia Chen, Hua Jiang, Yuqiong Xie, Chunchun Li, Lihong Chen, Beibei Yang & Jiang Cao. (2020) Effective inhibition of cancer cells by recombinant adenovirus expressing EGFR-targeting artificial microRNA and reversed-caspase-3. PLOS ONE 15:8, pages e0237098.
Crossref
Crossref
Luciane T. Kagohara, Fernando Zamuner, Emily F. Davis-Marcisak, Gaurav Sharma, Michael Considine, Jawara Allen, Srinivasan Yegnasubramanian, Daria A. Gaykalova & Elana J. Fertig. (2020) Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines. British Journal of Cancer 123:1, pages 101-113.
Crossref
Crossref
Christian Sordo-Bahamonde, Massimo Vitale, Seila Lorenzo-Herrero, Alejandro López-Soto & Segundo Gonzalez. (2020) Mechanisms of Resistance to NK Cell Immunotherapy. Cancers 12:4, pages 893.
Crossref
Crossref
Fabio Andres, Martin Schwill, Ykelien L. Boersma & Andreas Plückthun. (2020) High-Throughput Generation of Bispecific Binding Proteins by Sortase A–Mediated Coupling for Direct Functional Screening in Cell Culture. Molecular Cancer Therapeutics 19:4, pages 1080-1088.
Crossref
Crossref
Vidhi Khanna, Jayanth Panyam & Thomas S Griffith. (2020) Exploiting antibody biology for the treatment of cancer. Immunotherapy 12:4, pages 255-267.
Crossref
Crossref
Sindhu Nair, Hoa Q. Trummell, Rajani Rajbhandari, Nanda K. Thudi, Susan E. Nozell, Jason M. Warram, Christopher D. Willey, Eddy S. Yang, William J. Placzek, James A. Bonner & Markus Bredel. (2020) Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer. PLOS ONE 15:2, pages e0229077.
Crossref
Crossref
Garima Singh, Kristof Zarschler, Sebastian Hunoldt, Irma Ivette Santana Martínez, Carmen L. Ruehl, Madlen Matterna, Ralf Bergmann, Domokos Máthé, Nikolett Hegedüs, Michael Bachmann, Peter Comba & Holger Stephan. (2020)
Versatile Bispidine‐Based Bifunctional Chelators for
64
Cu
II
‐Labelling of Biomolecules
. Chemistry – A European Journal 26:9, pages 1989-2001.
Crossref
Crossref
Lidia M. Andrade, Estefânia M.N. Martins, Alice F. Versiani, Daniela S. Reis, Flavio G. da Fonseca, Ivina P.de Souza, Roberto M. Paniago, Elene Pereira-Maia & Luiz O. Ladeira. (2020) The physicochemical and biological characterization of a 24-month-stored nanocomplex based on gold nanoparticles conjugated with cetuximab demonstrated long-term stability, EGFR affinity and cancer cell death due to apoptosis. Materials Science and Engineering: C 107, pages 110203.
Crossref
Crossref
Julie A. Hixon, Caroline Andrews, Lila Kashi, Casey L. Kohnhorst, Emilee Senkevitch, Kelli Czarra, Joao T. Barata, Wenqing Li, Joel P. Schneider, Scott T. R. Walsh & Scott K. Durum. (2019) New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models. Leukemia 34:1, pages 35-49.
Crossref
Crossref
Ting Shen & Qiang Guo. (2019) EGFR signaling pathway occupies an important position in cancer‐related downstream signaling pathways of Pyk2. Cell Biology International 44:1, pages 2-13.
Crossref
Crossref
Simon Vyse & Paul H. Huang. (2019) Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduction and Targeted Therapy 4:1.
Crossref
Crossref
Martin D. Forster, Magnus T. Dillon, Judit Kocsis, Éva Remenár, Gabor Pajkos, Frederic Rolland, Jonathan Greenberg & Kevin J. Harrington. (2019) Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study. European Journal of Cancer 123, pages 36-47.
Crossref
Crossref
William J. McDaid, Michelle K. Greene, Michael C. Johnston, Ellen Pollheimer, Peter Smyth, Kirsty McLaughlin, Sandra Van Schaeybroeck, Robert M. Straubinger, Daniel B. Longley & Christopher J. Scott. (2019) Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours. Nanoscale 11:42, pages 20261-20273.
Crossref
Crossref
Lilla Pethő, József Murányi, Kinga Pénzes, Bianka Gurbi, Diána Brauswetter, Gábor Halmos, Gabriella Csík & Gábor Mező. (2019) Suitability of GnRH Receptors for Targeted Photodynamic Therapy in Head and Neck Cancers. International Journal of Molecular Sciences 20:20, pages 5027.
Crossref
Crossref
Rosita Russo, Nunzia Matrone, Valentina Belli, Davide Ciardiello, Mariangela Valletta, Sabrina Esposito, Paolo Vincenzo Pedone, Fortunato Ciardiello, Teresa Troiani & Angela Chambery. (2019) Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells. Cancers 11:10, pages 1430.
Crossref
Crossref
Ofra Novoplansky, Matthew Fury, Manu Prasad, Ksenia Yegodayev, Jonathan Zorea, Limor Cohen, Raphael Pelossof, Liz Cohen, Nora Katabi, Fabiola Cecchi, Ben-Zion Joshua, Aron Popovtzer, Jose Baselga, Maurizio Scaltriti & Moshe Elkabets. (2019) MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. International Journal of Cancer 145:3, pages 748-762.
Crossref
Crossref
Raquel BenedettoAdriana V.F. MassicanoBryant K. CrenshawRenato OliveiraRui M. ReisElaine B. AraújoSuzanne E. Lapi. (2019)
89
Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
. Cancer Biotherapy and Radiopharmaceuticals 34:5, pages 288-296.
Crossref
Crossref
Rama Soundararajan, Jared Fradette, Jessica Konen, Stacy Moulder, Xiang Zhang, Don Gibbons, Navin Varadarajan, Ignacio Wistuba, Debasish Tripathy, Chantale Bernatchez, Lauren Byers, Jeffrey Chang, Alejandro Contreras, Bora Lim, Edwin Parra, Emily Roarty, Jing Wang, Fei Yang, Michelle Barton, Jeffrey Rosen & Sendurai Mani. (2019) Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers 11:5, pages 714.
Crossref
Crossref
Nadja Groysbeck, Audrey Stoessel, Mariel Donzeau, Elisabete Cruz da Silva, Maxime Lehmann, Jean-Marc Strub, Sarah Cianferani, Kassiogé Dembélé & Guy Zuber. (2019) Synthesis and biological evaluation of 2.4 nm thiolate-protected gold nanoparticles conjugated to Cetuximab for targeting glioblastoma cancer cells via the EGFR. Nanotechnology 30:18, pages 184005.
Crossref
Crossref
Raimond Heukers, Vida Mashayekhi, Mercedes Ramirez-Escudero, Hans de Haard, Theo Verrips, Paul. van Bergen en Henegouwen & Sabrina Oliveira. (2019) VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells. Antibodies 8:2, pages 26.
Crossref
Crossref
Wei-Siang Liao, Yu Ho, Yu-Wei Lin, Emmanuel Naveen Raj, Kuang-Kai Liu, Chinpiao Chen, Xiao-Zhen Zhou, Kun-Ping Lu & Jui-I Chao. (2019) Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite. Acta Biomaterialia 86, pages 395-405.
Crossref
Crossref
Mehri Ghasabi, Behzad Mansoori, Ali Mohammadi, Pascal HG Duijf, Navid Shomali, Naghmeh Shirafkan, Ahad Mokhtarzadeh & Behzad Baradaran. (2018) MicroRNAs in cancer drug resistance: Basic evidence and clinical applications. Journal of Cellular Physiology 234:3, pages 2152-2168.
Crossref
Crossref
Jasmin B. Post, Nizar Hami, Alexander E.E. Mertens, Suraya Elfrink, Johannes L. Bos & Hugo J.G. Snippert. (2019) CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition. Oncotarget 10:14, pages 1440-1457.
Crossref
Crossref
Anuratha Sakthianandeswaren, Polly Sabljak, Meg J. Elliott, Michelle Palmieri & Oliver M. Sieber. 2019. Advances in the Molecular Understanding of Colorectal Cancer. Advances in the Molecular Understanding of Colorectal Cancer.
Hakan Gurdal, Matilda Tuglu, Saber Bostanabad & Başak Dalkili�. (2019) Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple‑negative breast cancer cell lines. International Journal of Oncology.
Crossref
Crossref
Magnus T. Dillon, Lorna Grove, Kate L. Newbold, Heather Shaw, Nicholas F. Brown, Jeanne Mendell, Shuquan Chen, Robert A. Beckman, Anne Jennings, Marivic Ricamara, Jonathan Greenberg, Martin Forster & Kevin J. Harrington. (2019) Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study. Clinical Cancer Research 25:2, pages 487-495.
Crossref
Crossref
David M. Vail, Douglas H. Thamm & Julias M. Liptak. 2019. Withrow and MacEwen's Small Animal Clinical Oncology. Withrow and MacEwen's Small Animal Clinical Oncology
251
285
.
Snehangshu Kundu, Muhammad Akhtar Ali, Niklas Handin, Narendra Padhan, Jimmy Larsson, Maria Karoutsou, Kenneth Ban, Jacek R. Wiśniewski, Per Artursson, Liqun He, Mats Hellström & Tobias Sjöblom. (2018) Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells. Genome Medicine 10:1.
Crossref
Crossref
Emily K. Kleczko & Lynn E. Heasley. (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Molecular Cancer 17:1.
Crossref
Crossref
R. Galot, C. Le Tourneau, J. Guigay, L. Licitra, I. Tinhofer, A. Kong, C. Caballero, C. Fortpied, J. Bogaerts, A.-S. Govaerts, D. Staelens, T. Raveloarivahy, L. Rodegher, J.-F. Laes, E. Saada-Bouzid & J.-P. Machiels. (2018) Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach. Annals of Oncology 29:12, pages 2313-2327.
Crossref
Crossref
Dan P. Zandberg & Robert L. Ferris. (2018) Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits. Current Treatment Options in Oncology 19:12.
Crossref
Crossref
Sergio González Rubio, Nuria Montero Pastor, Carolina García, Víctor G. Almendro-Vedia, Irene Ferrer, Paolo Natale, Luis Paz-Ares, M. Pilar Lillo & Iván López-Montero. (2018) Enhanced Cytotoxic Activity of Mitochondrial Mechanical Effectors in Human Lung Carcinoma H520 Cells: Pharmaceutical Implications for Cancer Therapy. Frontiers in Oncology 8.
Crossref
Crossref
Hester A. Doyle, Raymond A. Koski, Nathalie Bonafé, Ross A. Bruck, Stephanie M. Tagliatela, Renelle J. Gee & Mark J. Mamula. (2018) Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3. Cancer Immunology, Immunotherapy 67:10, pages 1559-1569.
Crossref
Crossref
Brandon Leonard, Toni M. Brand, Rachel A. O'Keefe, Eliot D. Lee, Yan Zeng, Jacquelyn D. Kemmer, Hua Li, Jennifer R. Grandis & Neil E. Bhola. (2018) BET Inhibition Overcomes Receptor Tyrosine Kinase–Mediated Cetuximab Resistance in HNSCC. Cancer Research 78:15, pages 4331-4343.
Crossref
Crossref
Addys González Palomo, Armando López Medinilla, Valeria Segatori, María del Carmen Barroso, Rances Blanco, Mariano R. Gabri, Adriana Carr Pérez & Kalet León Monzón. (2018) Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3. Oncotarget 9:35, pages 24069-24080.
Crossref
Crossref
V. Vigneswara & A. Kong. (2018) Predictive biomarkers and EGFR inhibitors in squamous cell carcinoma of head and neck (SCCHN). Annals of Oncology 29:4, pages 794-796.
Crossref
Crossref
Sabrina Maisel, Derrick Broka & Joyce Schroeder. (2017) Intravesicular epidermal growth factor receptor subject to retrograde trafficking drives epidermal growth factor-dependent migration. Oncotarget 9:5, pages 6463-6477.
Crossref
Crossref
Jessica M. Moskovitz & Robert L. Ferris. 2018. Critical Issues in Head and Neck Oncology. Critical Issues in Head and Neck Oncology
341
355
.
Livio Trusolino & Simonetta M. Leto. 2018. Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways. Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
1
27
.
Levi Arnold, Jonathan Enders & Sufi Thomas. (2017) Activated HGF-c-Met Axis in Head and Neck Cancer. Cancers 9:12, pages 169.
Crossref
Crossref
Matilda Tuglu, Saber Bostanabad, Gozde Ozyon, Başak Dalkili� & Hakan Gurdal. (2017) The role of dual‑specificity phosphatase 1 and protein phosphatase�1 in β2‑adrenergic receptor‑mediated inhibition of extracellular signal regulated kinase 1/2 in triple negative breast cancer cell lines. Molecular Medicine Reports.
Crossref
Crossref
Yu-Wei Lin, Emmanuel Naveen Raj, Wei-Siang Liao, Johnson Lin, Kuang-Kai Liu, Ting-Hua Chen, Hsiao-Chun Cheng, Chi-Ching Wang, Lily Yi Li, Chinpiao Chen & Jui-I Chao. (2017) Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition. Scientific Reports 7:1.
Crossref
Crossref
A. Hollebecque, R. Bahleda, L. Faivre, J. Adam, V. Poinsignon, A. Paci, C. Gomez-Roca, J.C. Thery, M.C. Le Deley, A. Varga, A. Gazzah, E. Ileana, M. Gharib, E. Angevin, K. Malekzadeh, C. Massard, J.C. Soria & J.P. Spano. (2017) Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours. European Journal of Cancer 81, pages 81-89.
Crossref
Crossref
Diego Alvarado, Gwenda F. Ligon, Jay S. Lillquist, Scott B. Seibel, Gerald Wallweber, Veronique M. Neumeister, David L. Rimm, Gerald McMahon & Theresa M. LaVallee. (2017) ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC. PLOS ONE 12:7, pages e0181356.
Crossref
Crossref
L.P. Stabile, A.M. Egloff, M.K. Gibson, W.E. Gooding, J. Ohr, P. Zhou, N.J. Rothenberger, L. Wang, J.L. Geiger, J.T. Flaherty, J.R. Grandis & J.E. Bauman. (2017) IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer. Oral Oncology 69, pages 38-45.
Crossref
Crossref
Evangelos Koustas, Michalis V. Karamouzis, Chrysovalantou Mihailidou, Dimitrios Schizas & Athanasios G. Papavassiliou. (2017) Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer. Cancer Letters 396, pages 94-102.
Crossref
Crossref
A Dokala & S S Thakur. (2016) Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery. Oncogene 36:17, pages 2337-2344.
Crossref
Crossref
Julie E. Bauman, Umamaheswar Duvvuri, William E. Gooding, Tanya J. Rath, Neil D. Gross, John Song, Antonio Jimeno, Wendell G. Yarbrough, Faye M. Johnson, Lin Wang, Simion Chiosea, Malabika Sen, Jason Kass, Jonas T. Johnson, Robert L. Ferris, Seungwon Kim, Fred R. Hirsch, Kimberly Ellison, John T. Flaherty, Gordon B. Mills & Jennifer R. Grandis. (2017) Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. JCI Insight 2:6.
Crossref
Crossref
Mariangela De Robertis, Luisa Loiacono, Caterina Fusilli, Maria Luana Poeta, Tommaso Mazza, Massimo Sanchez, Luigi Marchionni, Emanuela Signori, Giuseppe Lamorte, Angelo Luigi Vescovi, Jesus Garcia-Foncillas & Vito Michele Fazio. (2017) Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer. Clinical Cancer Research 23:1, pages 159-170.
Crossref
Crossref
María José Serrano, María Jesús Alvarez-Cubero, Diego De Miguel Pérez, Alba Rodríguez-Martínez, Lucas Gonzalez-Herrera, Inmaculada Robles-Fernandez, José Exposito Hernandez, Jose Luis García Puche & José Antonio Lorente. 2017. Isolation and Molecular Characterization of Circulating Tumor Cells. Isolation and Molecular Characterization of Circulating Tumor Cells
285
296
.
Shi Hu, Haibin Dai, Tian Li, Ying Tang, Wenyan Fu, Qingning Yuan, Feifei Wang, Gaojian Lv, Yuanyuan Lv, Xiaoyan Fan, Sheng Zhang, Ruobing Jin, Yafeng Shen, Fangxing Lin, Xuting Ye, Min Ding, Yongji Yang & Changhai Lei. (2016) Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. Cancer Letters 382:1, pages 32-43.
Crossref
Crossref
�ngela Riffo-Campos, Josefa Castillo, Azahara Vallet-S�nchez, Guillermo Ayala, Andr�s Cervantes, Gerardo L�pez-Rodas & Luis Franco. (2016) In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells. Oncology Reports.
Crossref
Crossref
Mari Iida, Harsh Bahrar, Toni M. Brand, Hannah E. Pearson, John P. Coan, Rachel A. Orbuch, Bailey G. Flanigan, Adam D. Swick, Prashanth J. Prabakaran, Johan Lantto, Ivan D. Horak, Michael Kragh, Ravi Salgia, Randy J. Kimple & Deric L. Wheeler. (2016) Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Molecular Cancer Therapeutics 15:9, pages 2175-2186.
Crossref
Crossref
Yoshihiro Ohashi, Kenichi Kumagai, Yukinaga Miyata, Ryota Matsubara, Kazutaka Kitaura, Satsuki Suzuki, Yoshiki Hamada & Ryuji Suzuki. (2016) Overexpression of ErbB4 is an independent marker for lymph node metastasis in Japanese patients with oral squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 122:3, pages 313-321.
Crossref
Crossref
Yvonne Möller, Markus Morkel, Jens Schmid, Sven Beyes, Janina Hendrick, Michaela Strotbek, Pamela Riemer, Simone Schmid, Lisa C. Schmitt, Roland Kontermann, Thomas Mürdter, Matthias Schwab, Christine Sers & Monilola A. Olayioye. (2016) Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling. Oncotarget 7:33, pages 53526-53539.
Crossref
Crossref
Mengmeng Yang, Xiaoxi Xu, Jie Cai, Jinying Ning, Jean Pierre Wery & Qi‐Xiang Li. (2016)
NSCLC harboring EGFR exon‐20 insertions after the regulatory
C
‐helix of kinase domain responds poorly to known EGFR inhibitors
. International Journal of Cancer 139:1, pages 171-176.
Crossref
Crossref
Silvia Carvalho, Francesca Levi-Schaffer, Michael Sela & Yosef Yarden. (2016) Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. British Journal of Pharmacology 173:9, pages 1407-1424.
Crossref
Crossref
Xiaojun Tan, Paul F. Lambert, Alan C. Rapraeger & Richard A. Anderson. (2016) Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications. Trends in Cell Biology 26:5, pages 352-366.
Crossref
Crossref
G. Paolo Dotto & Anil K. Rustgi. (2016) Squamous Cell Cancers: A Unified Perspective on Biology and Genetics. Cancer Cell 29:5, pages 622-637.
Crossref
Crossref
Shiva Ahdi Khosroshahi, Safar Farajnia, Mehdi Ghiamirad, Asghar Tanomand, Kamal Veisi, Leila Rahbarnia & Bahman Akbari. (2016) Development and evaluation of a single domain antibody against human epidermal growth factor receptor (EGFR). Protein Expression and Purification 120, pages 59-64.
Crossref
Crossref
Michael J. Schell, Mingli Yang, Edoardo Missiaglia, Mauro Delorenzi, Charlotte Soneson, Binglin Yue, Michael V. Nebozhyn, Andrey Loboda, Gregory Bloom & Timothy J. Yeatman. (2016) A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome. Clinical Cancer Research 22:3, pages 734-745.
Crossref
Crossref
Simona Gurzu, Camelia Silveanu, Annamaria Fetyko, Vlad Butiurca, Zsolt Kovacs & Ioan Jung. (2016) Systematic review of the old and new concepts in the epithelial-mesenchymal transition of colorectal cancer. World Journal of Gastroenterology 22:30, pages 6764.
Crossref
Crossref
Ksenija Asić. (2016) Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies. Critical Reviews in Oncology/Hematology 97, pages 178-196.
Crossref
Crossref
Blake M. Warner & Jennifer Grandis. 2016. Targeting Oral Cancer. Targeting Oral Cancer
163
209
.
MADINIYAT NIYAZ, JURAT ANWER, HUI LIU, LIWEI ZHANG, ILYAR SHAYHEDIN & IDIRIS AWUT. (2015) Characterization of the expression and clinical features of epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in esophageal carcinoma. Oncology Letters 10:6, pages 3696-3704.
Crossref
Crossref
Chuang Du, Xin Wang, Junling Zhang, Xiangzheng Liu, Jing Zhu & Yucun Liu. (2015) Paxillin is positively correlated with the clinicopathological factors of colorectal cancer, and knockdown of Paxillin improves sensitivity to cetuximab in colorectal cancer cells. Oncology Reports.
Crossref
Crossref
Helle J. Jacobsen, Thomas T. Poulsen, Anna Dahlman, Ida Kjær, Klaus Koefoed, Jette W. Sen, Dietmar Weilguny, Bolette Bjerregaard, Christina R. Andersen, Ivan D. Horak, Mikkel W. Pedersen, Michael Kragh & Johan Lantto. (2015) Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity. Clinical Cancer Research 21:18, pages 4110-4122.
Crossref
Crossref
Anna Leonidova, Christian Foerster, Kristof Zarschler, Maik Schubert, Hans-Jürgen Pietzsch, Jörg Steinbach, Ralf Bergmann, Nils Metzler-Nolte, Holger Stephan & Gilles Gasser. (2015)
In vivo
demonstration of an active tumor pretargeting approach with peptide nucleic acid bioconjugates as complementary system
. Chemical Science 6:10, pages 5601-5616.
Crossref
Crossref
Ariel Pribluda, Cecile C. de la Cruz & Erica L. Jackson. (2015) Intratumoral Heterogeneity: From Diversity Comes Resistance. Clinical Cancer Research 21:13, pages 2916-2923.
Crossref
Crossref
Ji-Gang Wang, Juan Yu, Ji-Lin Hu, Wen-Lin Yang, Hong Ren, Di Ding, Lei Zhang & Xiu-Ping Liu. (2015) Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer. Cellular Signalling 27:7, pages 1315-1324.
Crossref
Crossref
Javier Martinez-Useros & Jesus Garcia-Foncillas. (2015) The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas. Oral Oncology 51:5, pages 423-430.
Crossref
Crossref
M. K. Petri, A. Brobeil, J. Planz, A. Bräuninger, S. Gattenlöhner, U. Nestler, A. Stenzinger, A. Paradowska & M. Wimmer. (2015) PTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor. Journal of Neuro-Oncology 123:1, pages 15-25.
Crossref
Crossref
Andrew P. Stein, Adam D. Swick, Molly A. Smith, Grace C. Blitzer, Robert Z. Yang, Sandeep Saha, Paul M. Harari, Paul F. Lambert, Cheng Z. Liu & Randall J. Kimple. (2015) Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies. Cancer Medicine 4:5, pages 699-712.
Crossref
Crossref
Igor F. Tsigelny, Jennifer J. Wheler, Jerry P. Greenberg, Valentina L. Kouznetsova, David J. Stewart, Lyudmila Bazhenova & Razelle Kurzrock. (2015) Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget 6:8, pages 6029-6039.
Crossref
Crossref
Yijia Wang, Chonglei Zhang, Yuquan Zhang, Hui Fang, Changjun Min, Siwei Zhu & X.-C. Yuan. (2015) Investigation of phase SPR biosensor for efficient targeted drug screening with high sensitivity and stability. Sensors and Actuators B: Chemical 209, pages 313-322.
Crossref
Crossref
Yaghoub Safdari, Masoumeh Khalili, Mohammad Ali Ebrahimzadeh, Yaghoub Yazdani & Safar Farajnia. (2015) Natural inhibitors of PI3K/AKT signaling in breast cancer: Emphasis on newly-discovered molecular mechanisms of action. Pharmacological Research 93, pages 1-10.
Crossref
Crossref
Stefan Kiesgen, Michaela A.E. Arndt, Christoph Körber, Ulrich Arnold, Tobias Weber, Niels Halama, Armin Keller, Benedikt Bötticher, Anne Schlegelmilch, Nora Liebers, Martin Cremer, Christel Herold-Mende, Gerhard Dyckhoff, Philippe A. Federspil, Alexandra D. Jensen, Dirk Jäger, Roland E. Kontermann, Walter Mier & Jürgen Krauss. (2015) An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo. Cancer Letters 357:1, pages 364-373.
Crossref
Crossref
Avisek Deyati, Shweta Bagewadi, Philipp Senger, Martin Hofmann-Apitius & Natalia Novac. (2015) Systems approach for the selection of micro-RNAs as therapeutic biomarkers of anti-EGFR monoclonal antibody treatment in colorectal cancer. Scientific Reports 5:1.
Crossref
Crossref
Mao-Yu Zhang, Jin-Jian Lu, Liang Wang, Zi-Chao Gao, Hao Hu, Carolina Oi Lam Ung & Yi-Tao Wang. (2015) Development of Monoclonal Antibodies in China: Overview and Prospects. BioMed Research International 2015, pages 1-10.
Crossref
Crossref
Shijun Zhu, Walter Kisiel, Yang J. Lu, Lars C. Petersen, John M. Ndungu, Terry W. Moore, Ernest T. Parker, Aiming Sun, Dennis C. Liotta, Bassel F. El-Rayes, Daniel J. Brat, James P. Snyder & Mamoru Shoji. (2014) Tumor Angiogenesis Therapy Using Targeted Delivery of Paclitaxel to the Vasculature of Breast Cancer Metastases. Journal of Drug Delivery 2014, pages 1-12.
Crossref
Crossref
Mohamed Altai, Hadis Honarvar, Helena Wållberg, Joanna Strand, Zohreh Varasteh, Maria Rosestedt, Anna Orlova, Finn Dunås, Mattias Sandström, John Löfblom, Vladimir Tolmachev & Stefan Ståhl. (2014) Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with 188Re. European Journal of Medicinal Chemistry 87, pages 519-528.
Crossref
Crossref
Kirtesh Patel, Jing Wen, Kelly Magliocca, Susan Muller, Yuan Liu, Zhuo Georgia Chen, Nabil Saba & Roberto Diaz. (2014) Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation. Cancer Chemotherapy and Pharmacology 74:5, pages 1015-1022.
Crossref
Crossref
Toni M. Brand, Mari Iida, Andrew P. Stein, Kelsey L. Corrigan, Cara M. Braverman, Neha Luthar, Mahmoud Toulany, Parkash S. Gill, Ravi Salgia, Randall J. Kimple & Deric L. Wheeler. (2014) AXL Mediates Resistance to Cetuximab Therapy. Cancer Research 74:18, pages 5152-5164.
Crossref
Crossref
Nicola Silvestris, Bruno Vincenzi, Anna Elisabetta Brunetti, Fotious Loupakis, Emanuela Dell'Aquila, Antonio Russo, Mario Scartozzi, Riccardo Giampieri, Stefano Cascinu, Vito Lorusso, Giuseppe Tonini, Alfredo Falcone & Daniele Santini. (2014) Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. Pharmacogenomics 15:13, pages 1701-1715.
Crossref
Crossref
YUICHI OHNISHI, YUKI MINAMINO, KENJI KAKUDO & MASAMI NOZAKI. (2014) Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency. Oncology Reports 32:2, pages 780-786.
Crossref
Crossref
Laura M. Rogers, Suresh Veeramani & George J. Weiner. (2014) Complement in monoclonal antibody therapy of cancer. Immunologic Research 59:1-3, pages 203-210.
Crossref
Crossref
Simonetta M. Leto & Livio Trusolino. (2014) Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. Journal of Molecular Medicine 92:7, pages 709-722.
Crossref
Crossref
MATEUSZ BUJKO, PAULINA KOBER, ANDRZEJ TYSAROWSKI, EWA MATYJA, TOMASZ MANDAT, WIESŁAW BONICKI & JANUSZ ALEKSANDER SIEDLECKI. (2014) EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas. Oncology Letters 7:6, pages 2019-2022.
Crossref
Crossref
G Garrido, A Rabasa, C Garrido, A López, L Chao, Á M García-Lora, F Garrido, L E Fernández & B Sánchez. (2013) Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms. Oncogene 33:24, pages 3129-3139.
Crossref
Crossref
M.J. Duffy, R. Lamerz, C. Haglund, A. Nicolini, M. Kalousová, L. Holubec & C. Sturgeon. (2013) Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. International Journal of Cancer 134:11, pages 2513-2522.
Crossref
Crossref
Yilong Yao, Yixue Xue, Jun Ma, Chao Shang, Ping Wang, Libo Liu, Wenjing Liu, Zhen Li, Shengtao Qu, Zhiqing Li & Yunhui Liu. (2014) MiR-330-Mediated Regulation of SH3GL2 Expression Enhances Malignant Behaviors of Glioblastoma Stem Cells by Activating ERK and PI3K/AKT Signaling Pathways. PLoS ONE 9:4, pages e95060.
Crossref
Crossref
X. Tao, K.S. Hill, I. Gaziova, S.K. Sastry, S. Qui, P. Szaniszlo, S. Fennewald, V.A. Resto & L.A. Elferink. (2014) Silencing Met receptor tyrosine kinase signaling decreased oral tumor growth and increased survival of nude mice. Oral Oncology 50:2, pages 104-112.
Crossref
Crossref
Ning Li, Xiaohong Han, Ping Du, Yuanyuan Song, Xingsheng Hu, Sheng Yang & Yuankai Shi. (2014) Development and validation of a UPLC–MS/MS assay for the quantification of simotinib in human plasma. Analytical and Bioanalytical Chemistry 406:6, pages 1799-1805.
Crossref
Crossref
Carmen Berasain & Matías A. Avila. (2013) The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis. Journal of Gastroenterology 49:1, pages 9-23.
Crossref
Crossref
Brian G Blair, Alberto Bardelli & Ben Ho Park. (2014) Somatic alterations as the basis for resistance to targeted therapies. The Journal of Pathology 232:2, pages 244-254.
Crossref
Crossref
Christine A. Ciunci, Rodolfo F. Perini, Anjali N. Avadhani, Hyunseon C. Kang, Weijing Sun, Maryann Redlinger, Kathleen Harlacker, Keith T. Flaherty, Bruce J. Giantonio, Mark A. Rosen, Chaitanya R. Divgi, Hee Kwon Song, Sarah Englander, Andrea Troxel, Mitchell Schnall & Peter J. O'Dwyer. (2014) Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer 120:1, pages 77-85.
Crossref
Crossref
Woody Han, Richard L. Carpenter, Xinyu Cao & Hui-Wen Lo. (2013) STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation With STAT3. Molecular Carcinogenesis 52:12, pages 959-969.
Crossref
Crossref
Elizabeth M.H. Kim, Kelly Mueller, Elaina Gartner & Julie Boerner. (2013) Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells. Journal of Surgical Research 185:1, pages 231-239.
Crossref
Crossref
Yoonjung Kim, Juwon Kim, Hy-De Lee, Joon Jeong, Woochang Lee & Kyung-A Lee. (2013) Spectrum of EGFR Gene Copy Number Changes and KRAS Gene Mutation Status in Korean Triple Negative Breast Cancer Patients. PLoS ONE 8:10, pages e79014.
Crossref
Crossref
Mari Iida, Toni M Brand, Megan M Starr, Chunrong Li, Evan J Huppert, Neha Luthar, Mikkel W Pedersen, Ivan D Horak, Michael Kragh & Deric L Wheeler. (2013) Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab. Neoplasia 15:10, pages 1196-1206.
Crossref
Crossref
Jane Fridlyand, Richard M. Simon, Jessica C. Walrath, Nancy Roach, Richard Buller, David P. Schenkein, Keith T. Flaherty, Jeff D. Allen, Ellen V. Sigal & Howard I. Scher. (2013) Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nature Reviews Drug Discovery 12:10, pages 743-755.
Crossref
Crossref
Toni M. Brand, Mari Iida, Neha Luthar, Megan M. Starr, Evan J. Huppert & Deric L. Wheeler. (2013) Nuclear EGFR as a molecular target in cancer. Radiotherapy and Oncology 108:3, pages 370-377.
Crossref
Crossref
Lu-Ping Zhang, Xing-Yun Liao, Yan-Mei Xu, Lv-Jun Yan, Gui-Fang Yan, Xin-Xin Wang, Yu-Zhong Duan & Jian-Guo Sun. (2013)
Efficacy and Safety of Endostar
?
Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas
. Asian Pacific Journal of Cancer Prevention 14:7, pages 4255-4259.
Crossref
Crossref
Ina Hohensee, Katrin Lamszus, Sabine Riethdorf, Sönke Meyer-Staeckling, Markus Glatzel, Jakob Matschke, Isabell Witzel, Manfred Westphal, Burkhard Brandt, Volkmar Müller, Klaus Pantel & Harriet Wikman. (2013) Frequent Genetic Alterations in EGFR- and HER2-Driven Pathways in Breast Cancer Brain Metastases. The American Journal of Pathology 183:1, pages 83-95.
Crossref
Crossref
Lucinda S. Liu & Oscar R. Colegio. (2013) Molecularly targeted therapies for nonmelanoma skin cancers. International Journal of Dermatology 52:6, pages 654-665.
Crossref
Crossref
B. Kalman, E. Szep, F. Garzuly & D. E. Post. (2013) Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma. NeuroMolecular Medicine 15:2, pages 420-434.
Crossref
Crossref
Cheryl A. London. 2013. Advances in Veterinary Dermatology. Advances in Veterinary Dermatology
197
203
.
M Iida, T M Brand, D A Campbell, C Li & D L Wheeler. (2012) Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene 32:6, pages 759-767.
Crossref
Crossref
Cheryl A. London. (2013) Kinase dysfunction and kinase inhibitors. Veterinary Dermatology 24:1, pages 181-e40.
Crossref
Crossref
. 2013. Withrow and MacEwen's Small Animal Clinical Oncology. Withrow and MacEwen's Small Animal Clinical Oncology
215
244
.
Saba Wasim Aziz & Moammir Hasan Aziz. 2013. Breast Cancer Metastasis and Drug Resistance. Breast Cancer Metastasis and Drug Resistance
47
64
.
S. Bavcar & D. J. Argyle. (2012) Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy. Veterinary and Comparative Oncology 10:3, pages 163-173.
Crossref
Crossref
A. A. Stepanenko & V. M. Kavsan. (2012) Evolutionary karyotypic theory of cancer versus conventional cancer gene mutation theory. Biopolymers and Cell 28:4, pages 267-280.
Crossref
Crossref
Woody Han & Hui-Wen Lo. (2012) Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations. Cancer Letters 318:2, pages 124-134.
Crossref
Crossref
O. L. Polanovski, E. N. Lebedenko & S. M. Deyev. (2012) ERBB oncogene proteins as targets for monoclonal antibodies. Biochemistry (Moscow) 77:3, pages 227-245.
Crossref
Crossref
Li Du, Jingping Shen, Andrew Weems & Shi-Long Lu. (2012) Role of Phosphatidylinositol-3-Kinase Pathway in Head and Neck Squamous Cell Carcinoma. Journal of Oncology 2012, pages 1-12.
Crossref
Crossref
Ranee Mehra, Ilya G. Serebriiskii, Roland L. DunbrackJr.Jr., Matthew K. Robinson, Barbara Burtness & Erica A. Golemis. (2011) Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resistance Updates 14:6, pages 260-279.
Crossref
Crossref